DNA topoisomerase I relaxes supercoiled DNA by the formation of a covalent intermediate in which the active-site tyrosine is transiently bound to the cleaved DNA strand. The antineoplastic agent camptothecin specifically targets DNA topoisomerase I, and several mutations have been isolated that render the enzyme camptothecin-resistant. The catalytic and structural dynamical properties of a human DNA topoisomerase I mutant in which Ala-653 in the linker domain was mutated into Pro have been investigated. The mutant is resistant to camptothecin and in the absence of the drug displays a cleavage-religation equilibrium strongly shifted toward religation. The shift is mainly because of an increase in the religation rate relative to the wild type enzyme, indicating that the unperturbed linker is involved in slowing religation. Molecular dynamics simulation indicates that the Ala to Pro mutation increases the linker flexibility allowing it to sample a wider conformational space. The increase in religation rate of the mutant, explained by means of the enhanced linker flexibility, provides an explanation for the mutant camptothecin resistance.
DNA topoisomerase I (Top1p)1 catalyzes the relaxation of supercoiled DNA through the transient cleavage of one strand of a DNA duplex and is fundamental to processes such as replication, recombination, and transcription (1-4). The threedimensional structure of reconstituted and N-terminal truncated versions of human topoisomerase I (hTop1p) in complex with a 22-bp DNA molecule have shown that the enzyme is organized in multiple domains that "clamp" around the DNA molecule (5, 6). Changes in DNA topology are achieved by introducing a transient break in the phosphodiester bond of one strand in the duplex DNA. The phosphodiester bond energy is preserved during catalysis through the formation of a transient covalent phosphotyrosine bond between the catalytic Tyr-723 and the 3Ј end of the broken DNA strand. DNA relaxation has been proposed to proceed via "controlled rotation" in which the covalently bound enzyme holds one end of the DNA duplex and allows the end downstream of the cleavage site to rotate around the remaining phosphodiester bond (6). Eukaryotic Top1p is the cellular target of the anti-tumor drug camptothecin (CPT), which reversibly stabilizes the cleavable intermediate complex formed in the catalytic cycle of the enzyme (1, 2, 7).Recently Staker et al. (8) have solved the x-ray crystal structure of hTop1p covalently joined to double-stranded DNA and bound to the CPT analog Topotecan (8). This structure revealed that the drug molecule intercalates between upstream (Ϫ1) and downstream (ϩ1) bp, displacing the downstream DNA and thus preventing the religation of the cleaved strand. The structure helps to clarify the role of several, but not all, mutant residues that produce a CPT-resistant enzyme. In particular the structure permits to explain the CPT resistance for mutations involving residues that interact directly with the drug or that would alter the interaction with DNA...